Syra Health Corp. Class A Common Stock Stock Price: Quote, Forecast, Splits & News (SYRA)

Financial Profile

Prev Close

$0.11

Market Cap

$961.11K

Day Range

$0.08 - $0.08

Open

$0.08

P/E Ratio

-0.3

52W Range

$0.03 - $1.71

24H Volume

$331.42

Dividend Yield

0.00%

EPS

-0.32

Latest News

CaliberCos Inc. Completes 1-for-20 Reverse Stock Split Amid Fundraising Push

Jun 13, 2025

CaliberCos Inc. has executed a 1-for-20 reverse stock split, consolidating every 20 shares into one as it continues efforts to bolster fundraising and meet Nasdaq listing requirements. The move follows recent public offerings and signals the company’s drive to stabilize shares and attract new investment.

Syra Health Corp. Announces Voluntary Nasdaq Delisting as Board Seeks New CEO

Syra Health Corp. has begun the process of voluntarily delisting from the Nasdaq, citing strategic business reasons. The company’s board has also launched a search for a new CEO, marking a period of significant transition as it pursues population health contracts and new digital health initiatives.

Sagaliam Acquisition Corp. Liquidates Shares, Returns $10.75 per Share to Investors

Jun 13, 2025

Sagaliam Acquisition Corp. has completed its liquidation, crediting shareholders $10.7468 per share. This action follows a series of recent delistings and liquidations across the market, reflecting ongoing volatility and shifting investor sentiment in the SPAC and acquisition sector.

Key Issues

Earnings

Report Date

May 8, 2025

Reported Revenue

1.9M

Avg 1d Change

14.44%

Report Period

Q1 2025

Reported EPS

-0.04

Implied Move 1d

—

Transcript

9m 18s

And welcome, everyone. Thank you for joining our first quarter of twenty twenty five earnings call today. We value your continued interest in Syra Health and are excited to share updates on our recent performance and future goals. I will begin by highlighting our strong financial performance, followed by an update on our growth initiatives and strategic priorities for 2025. Then I will hand the call over to our Chief Financial Officer, Priyat Prasad, who will take you through a more detailed breakdown of her financial results. We enter 2025 with strong momentum following the solid trends experienced at the end of twenty twenty four. We are pleased with the successful execution of a strategy that is focused on capturing sustainable long term growth opportunities. In tandem with the continuation of diligent investments in key technological innovation. We delivered total revenue of 1,900,000.0 reflecting 6% annual growth compared to the first quarter of twenty twenty four. This was primarily driven by strong performance in our population health business unit which more than tripled from the year ago period. And represented 65% of total revenue versus the 19% contribution in the first quarter of twenty twenty four.

10m 45s

A strategic shift remains focused on targeting diversified high margin revenue streams while we continue to phase out more RTIA and care workforce contracts. I would like to highlight the strong gross margin trajectory in the quarter which expanded by 14.6 percentage points to 31.7%. The increase in gross margins was primarily driven by increased contribution from Population Health. Another benefit in the quarter was increased revenue from milestone driven projects However, we remain focused on the strategic shift in favor more sustainable long term recurring current contract revenue, which we believe will have a positive impact on our gross margins. Within population health, we signed a year long contract with a major insurance provider to enhance its plans for certain beneficiaries through streamlining of reporting processes, regulatory compliance assurance, and the provision of enhanced data insights. We have already initiated our work according to the contract terms, and experienced a steady increase in revenues that are estimated to reach 2 point

Key Insights

Total revenue for Q1 2025 was $1,900,000, reflecting 6% annual growth compared to Q1 2024.
The Population Health business unit drove growth, more than tripling year-over-year and now representing 65% of total revenue (up from 19% in Q1 2024).
Gross margin expanded by 14.6 percentage points to 31.7%, primarily due to increased contribution from Population Health.
The company is strategically shifting toward diversified, high-margin, recurring revenue streams and phasing out lower-margin RTIA and care workforce contracts.
A year-long contract was signed with a major insurance provider within Population Health, with revenues from this contract estimated to reach $2 million.